# Monika E. Hegi

Source: https://onco.cc/people/monika-hegi/  
OnCo record `monika-hegi` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Showed that MGMT promoter methylation predicts benefit from temozolomide, the biomarker every glioblastoma patient is now tested for.

## Summary

Monika Hegi led the 2005 NEJM study, companion to the Stupp trial, showing that glioblastoma patients with a methylated MGMT promoter gain most from temozolomide chemoradiotherapy, establishing the first predictive biomarker in neuro-oncology and the basis for treatment selection in elderly patients. She leads translational research for EORTC brain tumour trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: glioma; biomarkers; mgmt
- Role: Professor and Head of the Laboratory of Brain Tumor Biology and Genetics, Lausanne University Hospital (CHUV)
- Specialisms: Glioblastoma; MGMT methylation; Tumour biomarkers; Translational neuro-oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Hegi%20ME%5BAuthor%5D%20MGMT

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/)
- institutions: [Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne](https://onco.cc/institutions/chuv-lausanne/)
- trials: [EORTC 26981 / NCIC CE.3 (Stupp trial)](https://onco.cc/trials/eortc-26981/)
- key papers: [Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma](https://onco.cc/key-papers/paper-stupp-temozolomide-nejm-2005/)

---
JSON: https://onco.cc/api/v1/entities/monika-hegi.json